CBBYF:OTC-Virgin Money UK PLC (USD)

COMMON STOCK | | OTC

Last Closing Price

USD 1.24

Change

0.00 (0.00)%

Market Cap

USD 1.81B

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Virgin Money UK PLC provides banking products and services for consumers, and small and medium sized businesses under the Clydesdale Bank, Yorkshire Bank, and B and Virgin Money brands in the United Kingdom. The company offers savings accounts, mortgages, credit cards, current accounts, and home loans; business loans, overdraft facilities, treasury solutions, and corporate and structured finance; asset finance and wealth referral services; international trade services; currency services, pensions, and investments and protection products; and home, car, travel, and life and critical illness insurance. It also offers online and mobile banking, and telephone banking services. The company was formerly known as CYBG PLC and changed its name to Virgin Money UK PLC in October 2019. Virgin Money UK PLC was founded in 1838 and is headquartered in Glasgow, the United Kingdom.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-01 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BTHI Big Time Holdings, Inc

N/A

USD151.65B N/A N/A
HENOF Henkel AG & Co. KGaA

N/A

USD44.00B 15.83 N/A
SEMHF Siemens Healthineers AG

N/A

USD43.74B 30.16 N/A
DFIFF Diamond Fields Resources Inc

+0.02 (+22.67%)

USD43.14B 39.43 N/A
YACAF Yancoal Australia Ltd

N/A

USD41.57B 0.20 N/A
HDALF Haidilao International Holding..

N/A

USD37.30B 79.20 N/A
MQBKY Macquarie Group Limited

+2.06 (+2.02%)

USD37.00B 22.18 8.17
PETFF PTT Public Company Limited

N/A

USD34.53B 14.15 0.17
WXIBF WuXi Biologics (Cayman) Inc

N/A

USD33.35B 593.75 31.62
SARTF Sartorius Aktiengesellschaft

N/A

USD31.43B 114.64 N/A

ETFs Containing CBBYF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.15% N/A N/A 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.15% N/A N/A 43% F
Trailing 12 Months  
Capital Gain -8.15% N/A N/A 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.15% N/A N/A 42% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.51% N/A N/A 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.51% N/A N/A 21% F
Risk Return Profile  
Volatility (Standard Deviation) 20.03% N/A N/A 73% C
Risk Adjusted Return -42.49% N/A N/A 19% F
Market Capitalization 1.81B N/A N/A 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 51.40 N/A N/A 13% F
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -1.45 N/A N/A 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -2.83% N/A N/A 42% F
Return on Invested Capital 0.23% N/A N/A 40% F
Return on Assets -0.16% N/A N/A 50% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.99 N/A N/A 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.